Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- , a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will ...
Cogstate Announces Formation of Scientific Advisory Board Leading clinical and scientific experts in neurodegenerative diseases and pharmaceutical research will provide guidance to progress Cogstate’s strategy Melbourne, VIC, Australia; New Haven, CT, USA, June 14, 2022 (GLOBE NEWSWIRE) -- (ASX.CGS) a leading neuroscience technology company, today announced the formation of a Scientific Advisory Board (SAB), comprising clinical and scientific experts in cognitive assessment and drug development. The SAB will work closely with the Cogstate scientific leadership team to support the advan...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
A director at CogState Limited sold 2,250,000 shares at 0.900AUD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
BOSTON--(BUSINESS WIRE)-- The cognitive science company, Cogstate, today announced that its Healthcare Division recently received Health Canada marketing authorization for its latest Cognigram™ digital cognitive assessment system, and LifeSpring Physiotherapy, an Ontario-based concussion care leader has become the first Canadian implementation partner for the new Cognigram system. “LifeSpring is proud to offer concussion testing for individuals and teams using the Cognigram system. We intend to use the system to determ...
NEW HAVEN, Conn.--(BUSINESS WIRE)-- The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the appointment of Eric Siemers, M.D., as Distinguished Medical Adviser. Dr. Siemers will provide expert advice for Cogstate’s pharmaceutical customers with regard to the design of clinical trials of neurodegenerative diseases. He will support Cogstate’s ongoing participation in industry associations and public-private partnerships including the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Anti-Amyloid Treatment in A...
BOSTON--(BUSINESS WIRE)-- From the Interdisciplinary Conference on Orthopedic Value Based Care sponsored by the American College of Perioperative Medicine, Cogstate announced that the Cogstate Brief BatteryTM has now been shown to be useful for guiding decision making about cognitive outcomes in older adults awaiting or undergoing surgery. Cogstate Brief Battery is the proprietary technology utilized in the company’s CognigramTM digital cognitive assessment system, which is used extensively in the clinical assessment of dementia and c...
NEW HAVEN, Conn.--(BUSINESS WIRE)-- The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the addition of Dr. Chris Edgar, Senior Vice President, Clinical Science to its global scientific leadership team. Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy. He will provide expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through to final analysis. Dr. Edgar will also...
BOSTON--(BUSINESS WIRE)-- The cognitive science company, Cogstate today announced the commercial deployment of its Cognigram™ digital cognitive assessment system at the University of Notre Dame. This placement represents the first Cognigram system commercial implementation in the United States, following the recent FDA notification that the Company can begin marketing the system in the U.S. “We are thrilled that the University of Notre Dame decided to adopt our cognitive testing solution immediately after the Cognigram system...
BOSTON--(BUSINESS WIRE)-- The cognitive science company, Cogstate today announced that its healthcare division has received notification from the U.S. Food and Drug Administration (FDA) that the Company’s 510(k) submission (K171658) for the COGNIGRAM™ cognitive assessment system has been reviewed by the Center for Devices and Radiological Health and found to meet the requirements of regulations 21 CFR 882.1470; Class II Exempt Medical Device. This notification allows the company to market the medical device for commercial distribution...
NEW HAVEN, Conn.--(BUSINESS WIRE)-- The cognitive science company, Cogstate Ltd (ASX:CGS) today announced it has been chosen as the preferred provider to the global healthcare leader, Eli Lilly and Company, to support their Alzheimer disease platform with solutions to ensure high-quality neuropsychological outcome measures in clinical trials. Cogstate and Lilly will deploy an innovative program to improve the way that research sites train and collect endpoint data across Lilly’s portfolio of Alzheimer’s disease studies. ...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
NEW HAVEN, Conn. & PHILADELPHIA--(BUSINESS WIRE)-- Cognitive science company, Cogstate Ltd (ASX.CGS) and Clinical Ink, the leading provider of eSource and patient engagement technologies, today announced they have formalized their long-standing relationship with a strategic alliance that delivers enhanced tablet-based neuropsychological assessments for CNS clinical trials. The alliance combines, in a single solution, the scientific and adult learning expertise provided by Cogstate with the market-leading eSource data capture platform ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.